Steven H. Holtzman is EVP Corporate Development at BIOGEN INC. (BIIB). They have made 4 open-market trades across 1 company since 2007, most recently 2024-10-15.
CIK 0001300247
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $209K since 2007, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BIIB | SELL · 10b5-1 | 2015-02-17 | 2015-02-18 | $389.11 | $828K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-12-02 | 2014-12-03 | $335.65 | $587K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-11-11 | 2014-11-12 | $330.00 | $578K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-10-01 | 2014-10-02 | $330.97 | $579K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-05-19 | 2014-05-20 | $289.15 | $353K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-04-17 | 2014-04-21 | $291.00 | $355K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-03-17 | 2014-03-18 | $334.83 | $409K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2014-02-18 | 2014-02-19 | $327.90 | $401K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2013-09-17 | 2013-09-18 | $238.98 | $837K | -11.0% | -1.9% | -1.9% |
| INFI | SELL | 2012-05-31 | 2012-06-04 | $13.01 | $749K | -22.9% | -10.3% | -10.3% |
| INFI | SELL | 2012-05-29 | 2012-05-31 | $13.00 | $2.6M | -22.9% | -10.3% | -10.3% |
| INFI | BUY | 2008-08-27 | 2008-08-29 | $7.40 | $164K | -22.9% | -10.3% | -10.3% |
| INFI | BUY | 2007-09-14 | 2007-09-18 | $9.12 | $46K | -22.9% | -10.3% | -10.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.